

PATENT ASSIGNMENT

Electronic Version v1.1
Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY AGREEMENT
CONVEYING PARTY DATA	
Name	Execution Date
A.P. Pharma, Inc.	04/24/2011
RECEIVING PARTY DATA	
Name:	Tang Capital Partners, LP, as Agent
Street Address:	c/o Tang Capital Management, LLC; 4401 Eastgate Mall
City:	San Diego
State/Country:	CALIFORNIA
Postal Code:	92121
PROPERTY NUMBERS Total: 19	
Property Type	Number
Application Number:	12256408
Application Number:	12505457
Application Number:	12635681
Patent Number:	5316774
Patent Number:	5458890
Patent Number:	5939453
Patent Number:	5955109
Patent Number:	5968543
Patent Number:	6590059
Patent Number:	6613355
Patent Number:	6667371
Patent Number:	6670335
Patent Number:	6790458
Patent Number:	6822000
Patent Number:	6861068

501510825

PATENT
REEL: 026177 FRAME: 0874

CH \$760.00 12256408

Patent Number:	6863782
Patent Number:	7163694
Patent Number:	7220414
Patent Number:	7456213

CORRESPONDENCE DATA

Fax Number: (617)235-9492

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 617 951-7000

Email: mdipalma@ropesgray.com

Correspondent Name: Ropes & Gray LLP

Address Line 1: Prudential Tower 800 Boylston Street

Address Line 4: Boston, MASSACHUSETTS 02199-3600

ATTORNEY DOCKET NUMBER:	108954-0002
-------------------------	-------------

NAME OF SUBMITTER:	Mary Jane DiPalma
--------------------	-------------------

Total Attachments: 11

source=A.P. Pharma to Baker Bros entities#page1.tif
source=A.P. Pharma to Baker Bros entities#page2.tif
source=A.P. Pharma to Baker Bros entities#page3.tif
source=A.P. Pharma to Baker Bros entities#page4.tif
source=A.P. Pharma to Baker Bros entities#page5.tif
source=A.P. Pharma to Baker Bros entities#page6.tif
source=A.P. Pharma to Baker Bros entities#page7.tif
source=A.P. Pharma to Baker Bros entities#page8.tif
source=A.P. Pharma to Baker Bros entities#page9.tif
source=A.P. Pharma to Baker Bros entities#page10.tif
source=A.P. Pharma to Baker Bros entities#page11.tif

PATENT SECURITY AGREEMENT

This PATENT SECURITY AGREEMENT (this "Patent Security Agreement") is made this 24th day of April, 2011, among A.P. PHARMA, INC. ("Grantor"), and TANG CAPITAL PARTNERS, LP, in its capacity as representative for the Purchasers ("Agent").

RECITALS

WHEREAS, Pursuant to that certain Securities Purchase Agreement, dated as of April 24, 2011 (the "Securities Purchase Agreement"), by and among A.P. Pharma, Inc. ("Debtor"), Agent and Baker Bros. Investments II, L.P., Baker Brothers Life Sciences, L.P. and 14159, L.P., as Purchasers (collectively, the "Purchasers"), Debtor has agreed to issue to the Purchasers, and the Purchasers have agreed to purchase from Debtor, certain Secured Convertible Notes (the "Notes"), and

WHEREAS, the Purchasers are willing to make the financial accommodations to Debtor as provided for in the Securities Purchase Agreement and Notes, but only upon the condition, among others, that Grantor shall have executed and delivered to Agent, as representative of the Purchasers for the benefit of the Purchasers, that certain Security Agreement dated as of April 24, 2011 (including all annexes, exhibits or schedules thereto, as from time to time amended, restated, supplemented or otherwise modified, the "Security Agreement");

WHEREAS, pursuant to the Security Agreement, Grantor is required to execute and deliver to Agent this Patent Security Agreement;

NOW, THEREFORE, in consideration of the premises and mutual covenants herein contained and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Grantor hereby agrees as follows:

1. DEFINED TERMS. All capitalized terms used but not otherwise defined herein have the meanings given to them in the Security Agreement.

2. GRANT OF SECURITY INTEREST IN PATENT COLLATERAL. Grantor hereby grants to Agent a continuing first priority security interest in all of Grantor's right, title and interest in, to and under the following, whether presently existing or hereafter created or acquired (collectively, the "Patent Collateral");

(a) all of its Patents and Patent Intellectual Property Licenses to which it is a party including those referred to on Schedule I hereto;

(b) all reissues, continuations or extensions of the foregoing; and

(c) all products and proceeds of the foregoing, including any claim by Grantor against third parties for past, present or future infringement or dilution of any Patent or any Patent licensed under any Intellectual Property License.

3. SECURITY FOR OBLIGATIONS. This Patent Security Agreement and the Security Interest created hereby secures the payment and performance of all the Secured Obligations, whether now existing or arising hereafter. Without limiting the generality of the foregoing, this Patent Security Agreement secures the payment of all amounts which constitute part of the Secured Obligations and would be owed by Grantor, or any of them, to Agent, whether or not they are unenforceable or not allowable due to the existence of an Insolvency Proceeding involving Grantor.

4. SECURITY AGREEMENT. The security interests granted pursuant to this Patent Security Agreement are granted in conjunction with the security interests granted to Agent pursuant to the Security Agreement. Grantor hereby acknowledges and affirms that the rights and remedies of Agent with respect to the security interest in the Patent Collateral made and granted hereby are more fully set forth in the Security Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein.

5. AUTHORIZATION TO SUPPLEMENT. If Grantor shall obtain rights to any new patentable inventions or become entitled to the benefit of any patent application or patent for any reissue, division, or continuation, of any patent, the provisions of this Patent Security Agreement shall automatically apply thereto. Grantor shall give prompt notice in writing to Agent with respect to any such new patent rights. Without limiting Grantor's obligations under this Section 5, Grantor hereby authorizes Agent unilaterally to modify this Agreement by amending Schedule I to include any such new patent rights of Grantor. Notwithstanding the foregoing, no failure to so modify this Patent Security Agreement or amend Schedule I shall in any way affect, invalidate or detract from Agent's continuing security interest in all Collateral, whether or not listed on Schedule I.

6. COUNTERPARTS. This Patent Security Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original, but all such separate counterparts shall together constitute but one and the same instrument. In proving this Patent Security Agreement or any other Note Document in any judicial proceedings, it shall not be necessary to produce or account for more than one such counterpart signed by the party against whom such enforcement is sought. Any signatures delivered by a party by facsimile transmission or by e-mail transmission shall be deemed an original signature hereto.


7. CONSTRUCTION. Unless the context of this Patent Security Agreement or any other Note Document clearly requires otherwise, references to the plural include the singular, references to the singular include the plural, the terms "includes" and "including" are not limiting, and the term "or" has, except where otherwise indicated, the inclusive meaning represented by the phrase "and/or." The words "hereof," "herein," "hereby," "hereunder," and similar terms in this Patent Security Agreement or any other Note Document refer to this Patent Security Agreement or such other Note Document, as the

case may be, as a whole and not to any particular provision of this Patent Security Agreement or such other Note Document, as the case may be. Section, subsection, clause, schedule, and exhibit references herein are to this Patent Security Agreement unless otherwise specified. Any reference in this Patent Security Agreement or in any other Note Document to any agreement, instrument, or document shall include all alterations, amendments, changes, extensions, modifications, renewals, replacements, substitutions, joinders, and supplements, thereto and thereof, as applicable (subject to any restrictions on such alterations, amendments, changes, extensions, modifications, renewals, replacements, substitutions, joinders, and supplements set forth herein). Any reference herein or in any other Note Document to the satisfaction or repayment in full of the Secured Obligations shall mean the repayment in full in cash (or cash collateralization in accordance with the terms hereof) of all Obligations other than unasserted contingent indemnification Secured Obligations. Any reference herein to any Person shall be construed to include such Person's successors and assigns. Any requirement of a writing contained herein or in any other Note Document shall be satisfied by the transmission of a Record and any Record so transmitted shall constitute a representation and warranty as to the accuracy and completeness of the information contained therein.

[signature page follows]

IN WITNESS WHEREOF, Grantor has caused this Patent Security Agreement to be executed and delivered by its duly authorized officer as of the date first set forth above.

A.P. PHARMA, INC.

By: 
Name: John Whelan
Title: Acting Chief Executive Officer

ACCEPTED AND ACKNOWLEDGED BY:

TANG CAPITAL PARTNERS, LP,
as Agent

By: Tang Capital Management, LLC,
its general partner

By: 
Name: Kevin C. Tang
Title: Managing Director

Patent Security Agreement

PATENT
REEL: 026177 FRAME: 0880

SCHEDULE I
to
PATENT SECURITY AGREEMENT

Title	Country	Owner	Appl. No. Filing Date	Patent No. Issue Date
DEGRADABLE POLYACETAL POLYMERS	Australia	AP PHARMA, INC.	2001000088829 9/6/2001	188829 3/22/2002
BIOERODIBLE POLY(ORTHO ESTERS) CONTAINING AMINE GROUPS, AND BLOCK COPOLYMERS CONTAINING THEM	Australia	AP PHARMA, INC.	2002000352743 11/15/2002	2352743 6/10/2003
METHOD OF PREPARING DI(KETENE ACETALS)	Australia	A P PHARMA INC	2003000295558 11/13/2003	3295558 6/15/2004
BIOERODIBLE POLY(ORTHO ESTERS) FROM DIOXANE-BASED DI(KETENE ACETALS), AND BLOCK COPOLYMERS CONTAINING THEM	Australia	A P PHARMA INC	2003000295563 11/13/2003	3295563 6/15/2004
SEMI-SOLID DELIVERY VEHICLE AND PHARMACEUTICAL COMPOSITIONS	Australia	A.P. PHARMA, INC.	2005000289425 9/27/2005	5289425 4/6/2006
PEG-POLYACETAL DIBLOCK AND TRIBLOCK COPOLYMERS AND PHARMACEUTICAL COMPOSITIONS	Australia	AP PHARMA INC	2006000230201 3/28/2006	6230201 10/5/2006
PEG-POLY(ORTHO ESTER) GRAFT COPOLYMERS AND PHARMACEUTICAL COMPOSITIONS	Australia	AP PHARMA INC	2006000230226 3/28/2006	6230226 10/5/2006
PEG-POLYACETAL AND PEG- POLYACETAL-POE GRAFT COPOLYMERS AND PHARMACEUTICAL COMPOSITIONS	Australia	AP PHARMA INC	2006000230247 3/28/2006	6230247 10/5/2006
HALBFESTER VERABREICHUNGSTRÄGER UND ARZNEIMITTEL	Austria	AP PHARMA, INC.	001000935418 5/11/2001	311904 12/15/2005
ABBAUBARE POLYACETAL-POLYMERE	Austria	AP PHARMA INC	2001001968589 9/6/2001	377048 11/15/2007
BIOLOGISCH ABBAUBARE POLY(ORTHO- ESTER) VON DI(KETENACETALEN) AUF DIOXANGRUNDLAGE, SOWIE SIE ENTHALTENDE BLOCKCOPOLYMERE	Austria	A P PHARMA INC	2003003786759 11/13/2003	385801 3/15/2008
VERFAHREN ZUR HERSTELLUNG VON DIKETENACETALEN	Austria	A P PHARMA INC	2003003786754 11/13/2003	391115 4/15/2008
DEGRADABLE POLYACETAL POLYMERS	Canada	AP PHARMA, INC.	2001002453050 9/6/2001	2453050 3/14/2002
BIOERODIBLE POLY(ORTHO ESTERS) CONTAINING AMINE GROUPS, AND BLOCK COPOLYMERS CONTAINING THEM	Canada	AP PHARMA, INC.	2002002463179 11/15/2002	2463179 5/30/2003
METHOD OF PREPARING DI(KETENE ACETALS)	Canada	AP PHARMA INC	2003002506041 11/13/2003	2506041 6/3/2004
BIOERODIBLE POLY(ORTHO ESTERS) FROM DIOXANE-BASED DI(KETENE ACETALS), AND BLOCK COPOLYMERS CONTAINING THEM	Canada	A P PHARMA INC	2003002506241 11/13/2003	2506241 6/3/2004

SEMI-SOLID DELIVERY VEHICLE AND PHARMACEUTICAL COMPOSITIONS	Canada	AP PHARMA, INC.	2005002579297 9/27/2005	2579297 4/6/2006
PEG-POLYACETAL DIBLOCK AND TRIBLOCK COPOLYMERS AND PHARMACEUTICAL COMPOSITIONS	Canada	AP PHARMA INC	2006002601546 3/28/2006	2601546 10/5/2006
PEG-POLY(ORTHO ESTER) GRAFT COPOLYMERS AND PHARMACEUTICAL COMPOSITIONS	Canada	AP PHARMA INC	2006002601547 3/28/2006	2601547 10/5/2006
PEG-POLYACETAL AND PEG-POLYACETAL-POE GRAFT COPOLYMERS AND PHARMACEUTICAL COMPOSITIONS	Canada	AP PHARMA INC	2006002601548 3/28/2006	2601548 10/5/2006
SEMI-SOLID DELIVERY VEHICLE AND PHARMACEUTICAL COMPOSITIONS	China	A P PHARMA INC	2005080032680 9/27/2005	101052376 10/10/2007
PEG-POLYACETAL AND PEG-POLYACETAL-POE GRAFT COPOLYMERS AND PHARMACEUTICAL COMPOSITIONS	China	AP PHARMA INC	2006080011099 3/28/2006	101155844 4/2/2008
PEG-POLY(ORTHO ESTER) GRAFT COPOLYMERS AND PHARMACEUTICAL COMPOSITIONS	China	AP PHARMA INC	2006080009888 3/28/2006	101426529 5/6/2009
PEG-POLYACETAL DIBLOCK AND TRIBLOCK COPOLYMERS AND PHARMACEUTICAL COMPOSITIONS	China	AP PHARMA INC	2006080011030 3/28/2006	101495149 7/29/2009
BIOERODIBLE POLY(ORTHO ESTERS) FROM DIOXANE-BASED DI(KETENE ACETALS), AND BLOCK COPOLYMERS CONTAINING THEM	China	A P PHARMA INC	2003080106313 11/13/2003	1726043 1/25/2006
METHOD OF PREPARING DI(KETENE ACETALS)	China	A P PHARMA INC	2003080105821 11/13/2003	1726177 1/25/2006
HALVFAST INDGIVELSESVEHIKEL OG FARMACEUTISKE SAMMENSÆTNINGER	Denmark	AP PHARMA, INC.	2001000935418 5/11/2001	1280558 12/27/2005
POLYETHYLENE GLYCOL-POLYORTHOESTER, POLYETHYLENE GLYCOL-POLYORTHOESTER-POLYETHYLENE GLYCOL, AND POLYORTHOESTER-POLYETHYLENE GLYCOL-POLYORTHOESTER BLOCK COPOLYMERS	EU	AP Pharma, Inc.	1999000926034 5/28/1999	1084170 1/17/2007
SEMI-SOLID DELIVERY VEHICLE AND PHARMACEUTICAL COMPOSITIONS	EU	AP Pharma, Inc.	2001000935418 5/11/2001	1280558 12/7/2005
DEGRADABLE POLYACETAL POLYMERS	EU	AP Pharma, Inc.	2001000968589 9/6/2001	1315777 6/4/2003
BIOERODIBLE POLY(ORTHOESTERS) FROM DIOXOLANE-BASED DIKETENE ACETALS	EU	A.P. Pharma, Inc.	2002000734394 5/10/2002	1385485 2/4/2004
PEG-POE, PEG-POE-PEG, AND POE-PEG-POE BLOCK COPOLYMERS	EU	AP Pharma, Inc.	2002000736751 5/9/2002	1395626 3/10/2004
BIOERODIBLE POLY(ORTHO ESTERS) CONTAINING AMINE GROUPS, AND BLOCK COPOLYMERS CONTAINING THEM	EU	AP Pharma, Inc.	2002000789694 11/15/2002	1448666 8/25/2004

METHOD OF PREPARING DI(KETENE ACETALS)	EU	A.P. Pharma, Inc.	2003000786754 11/13/2003	1565419 8/24/2005
BIOERODIBLE POLY(ORTHO ESTERS) FROM DIOXANE-BASED DI(KETENE ACETALS), AND BLOCK COPOLYMERS CONTAINING THEM	EU	A.P. Pharma, Inc.	2003000786759 11/13/2003	1569664 9/7/2005
SEMI-SOLID DELIVERY VEHICLE AND PHARMACEUTICAL COMPOSITIONS	EU	AP PHARMA, INC.	2005000802951 9/27/2005	1796629 6/20/2007
PEG-POLYACETAL AND PEG-POLYACETAL-POE GRAFT COPOLYMERS AND PHARMACEUTICAL COMPOSITIONS	EU	AP PHARMA INC	2006000739903 3/28/2006	1863859 12/12/2007
PEG-POLYACETAL DIBLOCK AND TRIBLOCK COPOLYMERS AND PHARMACEUTICAL COMPOSITIONS	EU	AP PHARMA INC	2006000748831 3/28/2006	1865988 12/19/2007
PEG-POLY(ORTHO ESTER) GRAFT COPOLYMERS AND PHARMACEUTICAL COMPOSITIONS	EU	AP PHARMA INC	2006000748842 3/28/2006	1865989 12/19/2007
HALBFESTER VERABREICHUNGSTRÄGER UND ARZNEIMITTEL	Germany	AP PHARMA, INC.	2001060115631 5/11/2001	60115631 8/10/2006
ABBAUBARE POLYACETAL-POLYMERE	Germany	AP PHARMA INC	2001060131177 9/6/2001	60131177 8/7/2008
BIOLOGISCH ABBAUBARE AMIN-ENTHALTENDE POLYORTHOESTER UND BLOCKCOPOLYMERE DARAUS	Germany	AP PHARMA INC	2002060228875 11/15/2002	60228875C0 10/23/2008
BIOLOGISCH ABBAUBARE POLY(ORTHO-ESTER) VON DI(KETENACETALEN) AUF DIOXANGRUNDLAGE, SOWIE SIE ENTHALTENDE BLOCKCOPOLYMERE	Germany	A P PHARMA INC	2003060319128 11/13/2003	60319128 2/5/2009
VERFAHREN ZUR HERSTELLUNG VON DIKETENACETALEN	Germany	A P PHARMA INC	2003060320132 11/13/2003	60320132 5/20/2009
POLYETHYLENE GLYCOL-POLYORTHOESTER, POLYETHYLENE GLYCOL-POLYORTHOESTER-POLYETHYLENE GLYCOL, UND POLYORTHOESTER-POLYETHYLENE GLYCOL-POLYORTHOESTER BLOCKCOPOLYMERE	Germany	AP PHARMA INC	1999069934884 5/28/1999	69934884 10/18/2007
BIORODIBLE POLY(ORTHOESTERS) FROM DIOXOLANE-BASED DIKETENE ACETALS	International Register	A.P. PHARMA, INC.	2002US0015051 5/10/2002	02092061 11/21/2002
BIOERODIBLE POLY(ORTHOESTERS) CONTAINING HYDROGEN BONDING GROUPS	International Register	A.P. PHARMA, INC.	2002US0014964 5/10/2002	02092655 11/21/2002
PEG-POE, PEG-POE-PEG, AND POE-PEG-POE BLOCK COPOLYMERS	International Register	AP PHARMA, INC.	2002US0014945 5/9/2002	02092661 11/21/2002
DEGRADABLE POLYACETAL POLYMERS	International Register	AP PHARMA, INC.	2001US0027664 9/6/2001	0220663 5/10/2002
BIOERODIBLE POLY(ORTHO ESTERS) CONTAINING AMINE GROUPS, AND BLOCK COPOLYMERS CONTAINING THEM	International Register	AP PHARMA, INC.	2002US0036775 11/15/2002	03044076 7/29/2004

METHOD OF PREPARING DI(KETENE ACETALS)	International Register	A.P. PHARMA, INC.	2003US0036610 11/13/2003	04046074 6/3/2004
BIOERODIBLE POLY(ORTHO ESTERS) FROM DIOXANE-BASED DI(KETENE ACETALS), AND BLOCK COPOLYMERS CONTAINING THEM	International Register	A.P. PHARMA, INC.	2003US0036616 11/13/2003	04046328 8/26/2004
SEMI-SOLID DELIVERY VEHICLE AND PHARMACEUTICAL COMPOSITIONS	International Register	A.P. PHARMA, INC.	2005US0035117 9/27/2005	06037116 6/1/2006
PEG-POLYACETAL DIBLOCK AND TRIBLOCK COPOLYMERS AND PHARMACEUTICAL COMPOSITIONS	International Register	AP PHARMA, INC.	2006US0011343 3/28/2006	06105123 4/23/2009
PEG-POLY(ORTHO ESTER) GRAFT COPOLYMERS AND PHARMACEUTICAL COMPOSITIONS	International Register	AP PHARMA, INC.	2006US0011384 3/28/2006	06105148 12/13/2007
PEG-POLYACETAL AND PEG-POLYACETAL-POE GRAFT COPOLYMERS AND PHARMACEUTICAL COMPOSITIONS	International Register	AP PHARMA, INC.	2006US0011427 3/28/2006	06105172 11/1/2007
BASE-STABILIZED POLYORTHOESTER FORMULATIONS	International Register	A.P.PHARMA, INC.	2007US0011582 5/14/2007	2007133751 5/22/2008
FORMULATIONS OF 5-HT3 RECEPTOR ANTAGONISTS WITH POLYORTHOESTER FOR USE IN THE PREVENTION OF ACUTE AND DELAYED CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV)	International Register	A.P. PHARMA, INC.	2007US0011583 5/14/2007	2007133752 3/6/2008
METHODS FOR ENHANCING STABILITY OF POLYORTHOESTERS AND THEIR FORMULATIONS	International Register	A.P. PHARMA, INC.	2009US0067597 12/10/2009	2010068827 6/17/2010
METHOD OF PREPARING DI(KETENE ACETALS)	Korea	AP PHARMA INC	2005107008571 5/13/2005	2005074613 7/18/2005
BIOERODIBLE POLY(ORTHO ESTERS) FROM DIOXANE-BASED DI(KETENE ACETALS), AND BLOCK COPOLYMERS CONTAINING THEM	Korea	AP PHARMA INC	2005107008690 5/13/2005	2005075414 7/20/2005
SEMI-SOLID DELIVERY VEHICLE AND PHARMACEUTICAL COMPOSITIONS	Korea	A P PHARMA INC	2007107009728 4/27/2007	2007083851 8/24/2007
PEG-POLYACETAL DIBLOCK AND TRIBLOCK COPOLYMERS AND PHARMACEUTICAL COMPOSITIONS	Korea	AP PHARMA INC	2007107025073 10/30/2007	2007122519 12/31/2007
PEG-POLYACETAL AND PEG-POLYACETAL-POE GRAFT COPOLYMERS AND PHARMACEUTICAL COMPOSITIONS	Korea	AP PHARMA INC	2007107025149 10/30/2007	2007122521 12/31/2007
PEG-POLY(ORTHO ESTER) GRAFT COPOLYMERS AND PHARMACEUTICAL COMPOSITIONS	Korea	AP PHARMA INC	2007107025175 10/30/2007	2007122522 12/31/2007
VEHICULO DE ADMINISTRACION SEMI-SOLIDA Y COMPOSICIONES FARMACEUTICAS.	Spain	AP PHARMA INC	2001000935418 5/11/2001	2253381 6/1/2006

COPOLIMEROS DE BLOQUE DE POLIETILENGLICOL-POLIORTOESTER, POLIETILENGLICOL-POLIORTOESTER-POLIETILENGLICOL Y POLIORTOESTER-POLIETILENGLICOL-POLIORTOESTER.	Spain	AP PHARMA INC	1999099926034 5/28/1999	2281176 9/16/2007
POLIMEROS DEGRADABLES DE POLIACETAL.	Spain	AP PHARMA INC	2001001968589 9/6/2001	2294026 4/1/2008
POLI (ORTO-ESTERES) BIODEGRADABLES OBTENIDOS A PARTIR DE DI (CETENO-ACETALES) A BASE DIOXANO, Y COPOLIMEROS DE BLOQUE QUE LOS CONTIENEN.	Spain	A P PHARMA INC	2003003786759 11/13/2003	2299746 6/1/2008
METODO PARA LA OBTENCION DE ACETALES DE DICETENO.	Spain	A P PHARMA INC	2003003786754 11/13/2003	2302970 8/1/2008
POLI (ORTO-ESTERES) BIODEGRADABLES QUE CONTIENEN GRUPOS AMINA Y POLIMEROS DE BLOQUES QUE LOS CONTIENEN.	Spain	AP PHARMA INC	2002002789694 11/15/2002	2314118 3/16/2009
PEG-POLY(ORTHO ESTER) GRAFT COPOLYMERS AND PHARMACEUTICAL COMPOSITIONS	US	A.P. Pharma, Inc.	12/256408 10/22/08	
LONG-ACTING INJECTABLE ANALGESIC FORMULATIONS FOR ANIMALS	US	AP PHARMA and MERIAL LIMITED	12/505457 7/17/09	
METHODS FOR ENHANCING STABILITY OF POLYORTHOESTERS AND THEIR FORMULATIONS	US	A.P. Pharma, Inc.	12/635681 12/10/09	
BLOCKED POLYMERIC PARTICLES HAVING INTERNAL PORE NETWORKS FOR E DELIVERING ACTIVE SIBSTANCES TO SELECTED ENVIRONMENTS	US	A.P. PHARMA	07/806860 12/9/91	5316774 5/31/94
METHODS AND COMPOSITIONS FOR FLAVORING ORALLY-DELIVERED PRODUCTS	US	A.P. PHARMA	07/711259 6/4/91	5458890 10/17/95
PEG-POE, PEG-POE-PEG, AND POE-PEG-POE BLOCK COPOLYMERS	US	A.P. PHARMA	09/090648 6/4/98	5939453 8/17/99
METHODS AND COMPOSITIONS FOR TOPICAL DELIVERY OF RETINOIC ACID	US	A.P. PHARMA	08/079220 6/17/93	5955109 9/21/99
POLYMERS WITH CONTROLLED PHYSICAL STATE AND BIOERODIBILITY	US	A.P. PHARMA	08/986035 12/5/97	5968543 10/19/99
BIOERODIBLE POLYORTHOESTERS FROM DIOXOLANE-BASED DIKETENE ACETALS	US	AP PHARMA, INC.	09/854436 5/11/01	6590059 7/8/03
SEMI-SOLID DELIVERY VEHICLE AND PHARMACEUTICAL COMPOSITIONS	US	AP PHARMA, INC.	09/854180 5/11/01	6613355 9/2/03
BLOCK COPOLYMERS BASED ON POLY(ORTHO ESTERS) CONTAINING AMINE GROUPS	US	AP PHARMA, INC.	10/295766 11/14/02	6667371 12/23/03
FLUOROURACIL-CONTAINING FORMULATION	US	A.P. PHARMA	09/799792 3/5/01	6670335 12/30/03

PHARMACEUTICAL COMPOSITIONS USING SEMI-SOLID DELIVERY VEHICLE	US	AP Pharma Inc.	10/409408 4/7/03	6790458 9/14/2004
BIOERODIBLE POLY (ORTHOESTERS) FROM DIOXOLANE-BASED DIKETENE ACETALS	US	A.P. Pharma, Inc.	10/330781 12/24/02	6822000 11/23/2004
PHARMACEUTICAL COMPOSITIONS USING SEMI-SOLID DELIVERY VEHICLE	US	A.P. Pharma, Inc.	10/765768 1/26/04	6861068 3/1/2005
METHOD OF PREPARING DI(KETENE ACETALS)	US	AP PHARMA, INC.	10/298188 11/15/02	6863782 3/8/05
BIOERODIBLE POLY(ORTHO ESTERS) FROM DIOXANE-BASED DI(KETENE ACETALS), AND BLOCK COPOLYMERS CONTAINING THEM	US	A.P. Pharma, Inc.	11/371959 3/8/06	7163694 1/16/2007
DEGRADABLE POLYACETAL POLYMERS	US	AP PHARMA, INC.	09/949162 9/6/01	7220414 5/22/07
PEG-POLY(ORTHO ESTER) GRAFT COPOLYMERS AND PHARMACEUTICAL COMPOSITIONS	US	AP PHARMA, INC.	11/392989 3/28/06	7456213 11/25/08